BioLineRx Ltd.
BLRXBioLineRx Ltd. (Hebrew: ביוליין אר אקס), or BioLine, is a publicly traded drug development company. Headquartered in Israel, its shares are traded on the NASDAQ Capital Market and on the Tel Aviv Stock Exchange.
Drugs in Pipeline
9
Phase 3 Programs
1
Upcoming Catalysts
0
Next Catalyst
None scheduled
Market Overview
Stock performance and key metrics
0 upcoming, 0 past
No catalysts found.
BL-8040 1.25 mg/kg + G-CSF
Multiple Myeloma
horse anti-thymocyte globulin (hATG)
Aplastic Anemia
BL-7040
Ulcerative Colitis
BL - 1020
Schizophrenia
BL 1020 High Dose
Schizophrenia
Ara-C
Acute Myeloid Leukemia
BL-8040
Metastatic Pancreatic Adenocarcinoma
BL-1020
Schizophrenia
BL-7010
Celiac Disease
| Drug Name | Phase | Indication | Designations | Patent |
|---|---|---|---|---|
BL-8040 1.25 mg/kg + G-CSF | Phase 3 | Multiple Myeloma | - | - |
horse anti-thymocyte globulin (hATG) | Phase 2 | Aplastic Anemia | - | - |
BL-7040 | Phase 2 | Ulcerative Colitis | - | - |
BL - 1020 | Phase 2 | Schizophrenia | - | - |
BL 1020 High Dose | Phase 2 | Schizophrenia | - | - |
Ara-C | Phase 2 | Acute Myeloid Leukemia | - | - |
BL-8040 | Phase 2 | Metastatic Pancreatic Adenocarcinoma | - | - |
BL-1020 | Phase 2 | Schizophrenia | - | - |
BL-7010 | Phase 2 | Celiac Disease | - | - |
Source: CatalystAlert database (ClinicalTrials.gov, SEC EDGAR)
Frequently asked questions
What is in BioLineRx Ltd.'s drug pipeline?→
CatalystAlert tracks 9 drug candidates in BioLineRx Ltd.'s (BLRX) pipeline across Phase 3, Phase 2. Its lead program is BL-8040 1.25 mg/kg + G-CSF (Phase 3). Each drug's phase, indication and upcoming catalysts are listed on this page.
When is BioLineRx Ltd.'s next FDA catalyst?→
CatalystAlert tracks every upcoming catalyst for BioLineRx Ltd. (BLRX) — PDUFA decision dates, Phase 1/2/3 trial readouts, FDA advisory committee meetings and NDA/BLA filings — each confidence-rated as confirmed, estimated or AI-detected.
How do I track BLRX biotech catalysts?→
Add BLRX to your CatalystAlert watchlist for alerts ahead of each catalyst, and follow BioLineRx Ltd.'s live catalyst calendar, drug pipeline and clinical-trial timeline on this page — sourced from ClinicalTrials.gov, FDA and SEC filings.